Immune checkpoint inhibitors + anti-VEGF antibody/tyrosine kinase inhibitors (combination therapy) with or without transarterial chemoembolization (TACE)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Immune checkpoint inhibitors + anti-VEGF antibody/tyrosine kinase inhibitors (combination therapy) with or without transarterial chemoembolization (TACE), covering 2025-03-18 to 2025-03-18. Get the full timeline:
Most recent: Clinical Trial Update: Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions